Related Experiment Videos

Two years' experience using no-carrier-added meta-[123I]iodobenzylguanidine in clinical studies

M Knickmeier, M Schäfers, O Schober

European Journal of Nuclear Medicine

|October 5, 2001

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA.

European journal of nuclear medicine and molecular imaging·2021

Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.

Pediatric blood & cancer·2018

Worth a local treatment? - Analysis of modern radiotherapy concepts for oligometastatic prostate cancer.

Radiation oncology (London, England)·2018

[Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].

Der Urologe. Ausg. A·2018

External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.

EJNMMI research·2018

PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.

European journal of nuclear medicine and molecular imaging·2017

See all related articles